K
KBP Biosciences
A multinational clinical stage biotechnology company developing innovative therapies for unmet medical needs
About KBP Biosciences
KBP Biosciences is a globally recognized biotechnology company that focuses on the research and development of innovative therapies for unmet medical needs. The company operates in the pharmaceutical industry, serving patients suffering from hypertension, cardiorenal, and infectious diseases. KBP Biosciences uses a unique research and development platform to identify and develop products with significant differentiation. This platform is integrated with the company's compound library, allowing for efficient discovery and development of new drugs.
The company's business model is centered around the development of novel solutions for diseases and bringing these solutions from the laboratory to clinics worldwide. One of their recent achievements includes the completion of enrollment to its Phase 3 CLARION-CKD Study of Ocedurenone for uncontrolled hypertension in patients with advanced Chronic Kidney Disease (CKD). This shows the company's commitment to addressing critical health issues.
KBP Biosciences makes money by developing and selling these innovative therapies. The company's revenue comes from the sales of these drugs once they have been approved for use. The company also benefits from partnerships and collaborations with other entities in the pharmaceutical industry.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Jan 2018 | $76M | $304M | Korea Investment Partners · SDIC Fund Management Company · Sangel Capital · Cowin Capital | — |
Growth signals
Latest recorded traffic for KBP Biosciences is 670 monthly website visits, down 58.1% over the last three months. KBP Biosciences's team declined 2.2% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
KBP Biosciences in the Princeton ecosystem
The KBP Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A9 investors entered at this stage
SDIC Venture Capital- ACAdvantech Capital
Korea Investment Partners- SCSDIC Fund Management Company
Sangel Capital
Cowin Capital- BCBay City Capital
Ping An Ventures- ECElite Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about KBP Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See KBP Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








